Updated Interim Results from a Phase 1 Study of HPN217, a Half-Life Extended Tri-Specific T Cell Activating Construct (TriTAC®) Targeting B Cell Maturation Antigen (BCMA) for Relapsed/Refractory Multiple Myeloma (RRMM)
Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 7284-7285
10.1182/blood-2022-159665